🇺🇸 FDA
Pipeline program

CISPLATIN, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, GEMCITABINE, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, GEMCITABINE

D933SC00001

Phase 3 small_molecule active

Quick answer

CISPLATIN, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, GEMCITABINE, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, GEMCITABINE for Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials